Thus, we propose, in contrast to literature data [55], that the ability to selectively inhibit IL-8, but not CCL20, secretion may be a crucial property to consider in the screening of probiotic bacteria for their immunomodulatory activity, in order to identify the most suitable probiotic strains for long-term treatment of IBD. This evidence concerns the gene CXCL8 and inflammatory bowel disease.